股票 › GENB
生成生物医药 GENB
美股市值排名 #2859
$13.06 +$0.49 (+3.90%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $13.06 0.00%
开盘$12.90
昨收$12.57
当日区间$12.47 – $13.17
成交量632.2K
市值$1.68B
市盈率（TTM）–
股息率–
GENB 相关新闻
匹配 Generate Biomedicines 或代码 GENB 的头条新闻，按最新排序。
- Analysts Offer Insights on NA Companies: Guidewire (GWRE) and Generate Biomedicines, Inc. (GENB)
- Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24
- H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $25
- H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $30 正面
- Morgan Stanley Sticks to Its Buy Rating for Generate Biomedicines, Inc. (GENB)
- Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $22
- Guggenheim Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30
- Analysts Offer Insights on NA Companies: Yesway Inc Class A (YSWY), Generate Biomedicines, Inc. (GENB) and SK Hynix Inc. Sponsored GDR (OtherHXSCL)
- Guggenheim Reaffirms Their Buy Rating on Generate Biomedicines, Inc. (GENB)
- H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $25 正面
- Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)
- Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $22 正面
- H.C. Wainwright Initiates Generate Biomedicines(GENB.US) With Buy Rating, Announces Target Price $16
- Goldman Sachs Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $26 正面
- Guggenheim Initiates Generate Biomedicines(GENB.US) With Buy Rating, Announces Target Price $30
暂无评论——快来第一个聊聊 GENB。
登录后参与讨论。